BioCardia Inc (BCDA): Grabbed 1.20

Play Episode

25min

Proactive - Interviews for investors

Daniel Tillett on Race Oncology’s drug advancements

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection

Proactive - Interviews for investors

Clinical study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE

Medicus Pharma CEO Dr. Raza Bokhari joined Steve Darling from Proactive to share updates on the ongoing SKNJCT-003 clinical study, which is being conducted at nine sites across the United States and aims to randomize 60 patients. An interim analysis conducted after enrolling more than half of the targeted participants has shown encouraging results. The study reports a clinical clearance rate exceeding 60%, with the investigational therapy demonstrating strong tolerability across both tested dosage levels. Notably, no dose-limiting toxicities (DLTs) or serious adverse events (SAEs) have been observed, and there have been no systemic effects or clinically significant abnormalities in laboratory results, ECGs, vital signs, or physical exams. These promising findings will be submitted to the U.S. Food and Drug Administration (FDA) as part of a Type C meeting request in Q2 2025. In parallel, the company is advancing its clinical initiatives for non-invasive basal cell carcinoma treatment with a newly proposed study. This randomized, double-blind, placebo-controlled, multi-center trial has been submitted for approval to the UAE Department of Health. The study aims to enroll up to 36 patients at prominent medical institutions, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and the American Hospital of Dubai. Participants will be assigned in a 1:1:1 ratio to receive either a placebo or one of two dosage levels of the experimental treatment. This expansion into the UAE represents a significant step forward in the company’s mission to develop innovative, non-invasive therapies for skin cancer, broadening its global clinical footprint and reinforcing its commitment to advancing patient care. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch

Proactive - Interviews for investors

TNR Gold chair welcomes progress at McEwen Copper's Los Azules copper project in Argentina

TNR Gold Corp (TSX-V:TNR, OTC:TRRXF) executive chairman Kirill Klip talked with Proactive's Stephen Gunnion about the company’s latest developments, including a key milestone in its transition to a cash-flow-generating royalty business. Klip highlighted that TNR Gold holds royalties on significant projects, including the Los Azules Copper project and the Mariana Lithium project in Argentina. With Los Azules now applying for Argentina's incentive regime for large investments, he explained that the project could see substantial tax reductions, making it easier to attract the $2.7 billion investment required for construction. Discussing Argentina’s economic reforms under President Javier Milei, Klip noted that the country's policies are encouraging large-scale investment in the mining sector. He also pointed to the environmental permit secured for Los Azules, bringing it closer to a construction decision, with a feasibility study expected in the first half of the year. Klip also shared insights from Fundamental Research Corporation’s latest analysis, which increased its price target for TNR Gold from $0.24 to $0.28, underscoring the company's transition from a project generator to a cash-flow-generating royalty company. Watch the full interview for more insights into TNR Gold’s latest developments. For more interviews like this, subscribe to Proactive’s YouTube channel, give this video a like, and turn on notifications for future updates! #TNRGold #MiningInvesting #LosAzules #CopperMining #LithiumInvesting #MiningStocks #ArgentinaMining #RoyaltyCompany #StockMarket #JavierMilei

Proactive - Interviews for investors

KEFI Gold and Copper gets green light to progress with Tulu Kapi project in Ethiopia

KEFI Gold and Copper PLC executive chairman Harry Anagnostaras-Adams talked with Proactive about a major milestone for the company’s flagship Tulu Kapi gold project in Ethiopia. He described the latest announcement as the most significant since KEFI decided to focus on the Arabian Nubian Shield in 2008. Anagnostaras-Adams confirmed that all stakeholders in the project have now given the green light, marking the start of the next phase. He emphasised that there is no risk of being blocked, as land resettlement is progressing with the support of the local community. The process, involving thousands of people, is expected to be completed within a month, alongside final project preparations. He reiterated that the company has passed the “point of no return” and is now expediting the project’s launch. Investors seeking more details on KEFI’s technical, environmental, and financial studies can find extensive information on the company’s website: https://www.kefi-goldandcopper.com For more updates on KEFI Gold and Copper and other industry developments, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for the latest insights. Relevant Hashtags #KEFIGold #GoldMining #CopperMining #TuluKapi #EthiopiaMining #MiningInvestment #GoldStocks #ResourceSector #MiningUpdates #ProactiveInvestors

Followers	189
Posts	15062
Boards Moderated	0
Alias Born	08/26/2010

Volume:	23,147
Day Range:	2.45 - 2.63
Bid:	2.45
Ask:	2.60
Last Trade Time:	5:18:21 PM EDT
Total Trades:	237

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

BCDA Detailed Quote

Recent BCDA News

More BCDA News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent BCDA News

Go Ad-Free